Two Onc Docs

This week’s episode will be focusing on how we prepared the days leading up to our exam, wellness tips & a cheat sheet for some of the highest lead topics in lung cancer, breast cancer, vwF, hemoglobinopathies & more.

This week’s episode is a 2026 update focusing on metastatic breast cancer, including the preferred treatment options by receptor (ER/PR/HER2) status + key toxicities of different treatments.

This week’s episode will be focusing on treatment options for localized breast cancer. We will go all the important details on radiation, as well as therapies based on what the ER/PR/her2 receptor status is.

We are providing 2026 update for our breast cancer episodes, today we cover an introduction on breast cancer screening, prevention.

This week’s episode we are very excited to welcome back our special guest Dr. Hatim Husain, MD, a medical oncologist and physician-scientist at UC San Diego Moores Cancer Center, whose clinical and research expertise focuses on lung cancer and precision oncology. We further cover the topic of ctDNA, uses, limitations, and future directions.

This week’s episode we are very excited to welcome a special guest Dr. Hatim Husain, MD, a medical oncologist and physician-scientist at UC San Diego Moores Cancer Center, whose clinical and research expertise focuses on lung cancer and precision oncology. We cover the topic of liquid biopsies, ctDNA, NGS panels definitions & current uses.

This week's episode focuses on metastatic non-small cell lung cancer - the quickly growing and changing systemic therapy landscape, including traditional chemotherapy, immunotherapy, and targeted agents. Since our last recording the number of FDA-approved targeted drugs has significantly expanded.

This week's episode focuses on early-stage and locally advanced non-small cell lung cancer - staging, pathology, local and systemic therapy. Before we start, the usual caveat: the treatment landscape of NSCLC is changing FAST, which is exciting, but know that the boards run a few years behind. The big shifts since our last episode are the move to 9th-edition TNM staging and the arrival of four different perioperative chemo+immunotherapy regimens. Shout out to Dr. Bharathi Muthusamy for reviewing this episode to keep us current for 2026!

Today’s episode is focusing on what you need to know regarding myelodysplastic syndrome (MDS). This will include the high yield facts on risk factors, diagnostic work-up, staging and treatment of MDS, we were overdue do this this topic, last done in 2022.

This week’s episode will be focusing on syndromes of iron overload. We will go over all important details on hemochromatosis and other related diseases. We last covered this topic in 2023.

This week’s episode will be focusing on how to approach a newly diagnosed malignancy, biopsy, staging, patient considerations ect.

This week’s episode will be focusing on how to transition well into heme/onc fellowship including differences from residency, tips for surviving, wellness, resources & more.

This week’s episode will be focusing on Diffuse Large B-Cell Lymphoma (DLBCL). We will go all the important details on this aggressive NHL which can be highly curable. We have some new changes since we last covered this topic in 2022 including a new category 1 option for advanced DLBCL

This week’s episode we are back with our very special guest, friend and colleague Dr Laura Vater joining us to talk about wellness in oncology, and burnout prevention tips.

This week’s episode we have a very special guest, friend and colleague Dr. Laura Vater joining us to talk about one of the biggest transitions in medicine—moving from fellow to attending. Dr Vater is a GI oncologist at IU, writer, and speaker. She focuses on the dignity of patients and clinicians, and strives to keep healthcare human.

This week’s episode will be focusing on an ASCO 2026 Plenary abstract, SARC 041. SARC041 is the first positive phase 3 randomized controlled trial of a CDK4/6 inhibitor in advanced dedifferentiated liposarcoma (DDLPS), demonstrating that abemaciclib significantly improves progression-free survival compared to placebo.

Today we are recapping exciting GU data presented at the 2026 ASCO Annual Meeting in bladder cancer, kidney cancer, and prostate cancer.

This week’s episode will be focusing on the 2026 ASCO Plenary that received a standing ovation, the RASolute 302 trial. The RASolute 302 trial is a landmark phase 3 study demonstrating that daraxonrasib doubled overall survival compared to chemotherapy in previously treated (2L) metastatic pancreatic ductal adenocarcinoma (mPDAC).

Today we will be focusing on exciting data to come at the ASCO Annual Meeting in 2026 in Chicago, with a special focus on GU sessions, educational sessions & med ed sessions.

This week’s episode will be focusing on Von Willebrand disease (VWD), a highly testable bleeding disorder. We will go over all the important details on the diagnosis, types of VWD as well as treatment.